Table 2 Estimated annual net ingredient cost (NIC) savings € and % reduction as a proportion of overall NIC for effective and economical PPI prescribing (5 scenarios)
From: Proton pump inhibitors: potential cost reductions by applying prescribing guidelines
Scenarios (1 to 5) | Cost Savings (NIC) | % Overall (NIC) |
|---|---|---|
1 PPI initiation (least expensive brand) | €36,943,348 | 41.91 |
2 Therapeutic switching (cheaper brand, same dose) | €29,568,475 | 33.54 |
3 Dose reduction (maintenance) | €21,289,322 | 24.15 |
4 Therapeutic switching and dose reduction | €40,505,013 | 45.95 |
5 Therapeutic substitution (H2 Antagonist) | €34,991,569 | 39.69 |